FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tina Vilsbøll

Research Profile

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Mette Gyldenløve; Filip K Knop; Tina Vilsbøll; Claus Zachariae; Lone Skov
[Psoriasis is associated with type 2 diabetes].
David P Sonne; Tina Vilsbøll; Kristine J Hare; Jens J Holst; Pernille Martens; Jens F Rehfeld; Filip K Knop
Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
Annesofie Faurschou; Mette Gyldenløve; Jens J Holst; Jens Pedersen; Steen S Poulsen; Lone Skov; Jacob P Thyssen; Tina Vilsbøll; Claus Zachariae; Filip K Knop
Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tina Vilsbøll (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mette Gyldenløve; Filip K Knop; Tina Vilsbøll; Claus Zachariae; Lone Skov
[Psoriasis is associated with type 2 diabetes].
Ugeskrift for laeger 2013;175(10):652-4.
2013: David P Sonne; Tina Vilsbøll; Kristine J Hare; Jens J Holst; Pernille Martens; Jens F Rehfeld; Filip K Knop
Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
American journal of physiology. Gastrointestinal and liver physiology 2013;304(4):G413-9.
2013: Annesofie Faurschou; Mette Gyldenløve; Jens J Holst; Jens Pedersen; Steen S Poulsen; Lone Skov; Jacob P Thyssen; Tina Vilsbøll; Claus Zachariae; Filip K Knop
Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques.
Experimental dermatology 2013;22(2):150-2.
2013: Jens Juul Holst; Tina Vilsbøll
Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.
Diabetes, obesity & metabolism 2013;15(1):3-14.
2012: Morten Hansen; Filip Krag Knop; Thure Krarup; Asger Lund; Anders Rinnov Nielsen; Tina Vilsbøll; Henrik Vestergaard
Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes.
Pancreas 2012;41(8):1316-8.
2012: Mikkel Christensen; Tina Vilsbøll; Filip K Knop
[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
Ugeskrift for laeger 2012;174(34):1935; discussion 1935.
2012: Filip K Knop; Thure Krarup; K Aaboe; J J Holst; Tina Vilsbøll; A Vølund; Sten Madsbad
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Diabetes, obesity & metabolism 2012;14(6):500-10.
2012: Tina Vilsbøll; Alan J Garber
Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
Diabetes, obesity & metabolism 2012;14 Suppl 2():41-9.
2012: Katrine B Hansen; Jens J Holst; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
The Journal of clinical endocrinology and metabolism 2012;97(4):1363-70.
2012: Jacob Sivertsen; Jens J Holst; Jaya Rosenmeier; Tina Vilsbøll
The effect of glucagon-like peptide 1 on cardiovascular risk.
Nature reviews. Cardiology 2012;9(4):209-22.
2012: N A Rhee; Tina Vilsbøll; Filip K Knop
Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes.
Diabetes, obesity & metabolism 2012;14(4):291-8.
2012: Per Kappelgaard; Filip K Knop; Katrine B Hansen; Tina Vilsbøll; Michael Larsen
Electroretinography in healthy subjects in relation to systemic glucocorticoid intake.
Documenta ophthalmologica. Advances in ophthalmology 2012;124(1):49-57.
2012: Morten Hansen; Kristian Hallundbæk Mikkelsen; David Peick Sonne; Tina Vilsbøll; Lise Lotte Gluud; Filip Krag Knop
Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials.
BMJ open 2012;2(6):.
2011: Mikkel Christensen; Jens J Holst; Louise Vedtofte; Tina Vilsbøll; Filip K Knop
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Diabetes 2011;60(12):3103-9.
2011: Annesofie Faurschou; Lone Skov; Tina Vilsbøll; Claus Zachariae; Filip K Knop
Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?
Medical hypotheses 2011;77(6):1098-101.
2011: Mette Bøgelund; Jens Faber; Rasmus Prior Gjesing; Jan Erik Henriksen; Tina Vilsbøll; Morten Lammert
Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment.
Current medical research and opinion 2011;27(11):2175-83.
2011: J I Bagger; J J Holst; Filip K Knop; Tina Vilsbøll
Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
Diabetes, obesity & metabolism 2011;13(11):965-71.
2011: Asger Lund; Tina Vilsbøll; Jonatan I Bagger; Jens J Holst; Filip K Knop
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
American journal of physiology. Endocrinology and metabolism 2011;300(6):E1038-46.
2011: Jens J Holst; Filip K Knop; Tina Vilsbøll; Thure Krarup; Sten Madsbad
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
Diabetes care 2011;34 Suppl 2():S251-7.
2011: Mikkel Christensen; Filip K Knop; Tina Vilsbøll; Jens J Holst
Lixisenatide for type 2 diabetes mellitus.
Expert opinion on investigational drugs 2011;20(4):549-57.
2011: Jonatan I Bagger; Filip K Knop; Asger Lund; Henrik Vestergaard; Jens J Holst; Tina Vilsbøll
Impaired regulation of the incretin effect in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2011;96(3):737-45.
2011: Katrine B Hansen; Tina Vilsbøll; Jonatan I Bagger; Jens J Holst; Filip K Knop
Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
The Journal of clinical endocrinology and metabolism 2011;96(2):447-53.
2010: Filip K Knop; Tina Vilsbøll; Steen Larsen; Sten Madsbad; Jens Juul Holst; Thure Krarup
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.
Regulatory peptides 2010;164(2-3):144-50.
2010: Mikkel Christensen; Filip K Knop; Tina Vilsbøll; Kasper Aaboe; Jens J Holst; Sten Madsbad; Thure Krarup
Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.
Regulatory peptides 2010;163(1-3):96-101.
2010: Kristine J Hare; Tina Vilsbøll; Meena Asmar; Carolyn F Deacon; Filip K Knop; Jens J Holst
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
Diabetes 2010;59(7):1765-70.
2010: K Aaboe; Filip K Knop; Tina Vilsbøll; Carolyn F Deacon; Jens Juul Holst; Sten Madsbad; Thure Krarup
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism 2010;12(4):323-33.
2010: Kristine J Hare; Tina Vilsbøll; Jens J Holst; Filip K Knop
Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
American journal of physiology. Endocrinology and metabolism 2010;298(4):E832-7.
2010: Tina Vilsbøll; J Rosenstock; Hannele Yki-Järvinen; W T Cefalu; Y Chen; E Luo; B Musser; P J Andryuk; Y Ling; K D Kaufman; J M Amatruda; S S Engel; L Katz
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
Diabetes, obesity & metabolism 2010;12(2):167-77.
2010: Katrine B Hansen; Tina Vilsbøll; Filip K Knop
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.
Diabetes, metabolic syndrome and obesity : targets and therapy 2010;3():155-63.
2010: Filip K Knop; Tina Vilsbøll; Asger Lund; Thure Krarup; Jens J Holst; Mads Hornum
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency.
JOP : Journal of the pancreas 2010;11(5):489-91.
2009: Tina Vilsbøll
The effects of glucagon-like peptide-1 on the beta cell.
Diabetes, obesity & metabolism 2009;11 Suppl 3():11-8.
2009: Kristine J Hare; Filip K Knop; Meena Asmar; Sten Madsbad; Carolyn F Deacon; Jens J Holst; Tina Vilsbøll
Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.
The Journal of clinical endocrinology and metabolism 2009;94(12):4679-87.
2009: Michael A Nauck; Tina Vilsbøll; Baptist Gallwitz; Alan Garber; Sten Madsbad
Incretin-based therapies: viewpoints on the way to consensus.
Diabetes care 2009;32 Suppl 2():S223-31.
2009: Dario Giugliano; Eberhard Standl; Tina Vilsbøll; John Betteridge; Riccardo Bonadonna; Ian W Campbell; Gerit-Holger Schernthaner; Bart Staels; Antonia Trichopoulou; Eduardo Farinaro
Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?
Acta diabetologica 2009;46(3):173-81.
2009: Tina Vilsbøll; Jens J Holst; Filip K Knop
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
Best practice & research. Clinical endocrinology & metabolism 2009;23(4):453-62.
2009: K B Hansen; Filip K Knop; Jens Juul Holst; Tina Vilsbøll
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
International journal of clinical practice 2009;63(8):1154-60.
2009: Filip K Knop; Tina Vilsbøll; Jens J Holst
Incretin-based therapy of type 2 diabetes mellitus.
Current protein & peptide science 2009;10(1):46-55.
2008: Filip K Knop; Jens J Holst; Tina Vilsbøll
Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
IDrugs : the investigational drugs journal 2008;11(7):497-501.
2008: Jens J Holst; Carolyn F Deacon; Tina Vilsbøll; Thure Krarup; Sten Madsbad
Glucagon-like peptide-1, glucose homeostasis and diabetes.
Trends in molecular medicine 2008;14(4):161-8.
2008: Tina Vilsbøll; B Brock; H Perrild; K Levin; H-H Lervang; Klaus Kølendorf; Thure Krarup; O Schmitz; M Zdravkovic; T Le-Thi; Sten Madsbad
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association 2008;25(2):152-6.
2008: Tina Vilsbøll; Filip K Knop
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2008;22(4):251-7.
2007: Filip K Knop; Tina Vilsbøll; Patricia V Højberg; Steen Larsen; Sten Madsbad; Jens J Holst; Thure Krarup
The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Regulatory peptides 2007;144(1-3):123-30.
2007: Filip K Knop; Tina Vilsbøll; Patricia V Højberg; Steen Larsen; Sten Madsbad; Aage Voelund; Jens J Holst; Thure Krarup
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Diabetes 2007;56(8):1951-9.
2007: Tina Vilsbøll; Milan Zdravkovic; Tu Le-Thi; Thure Krarup; Ole Schmitz; Jean-Pierre Courrèges; Robert Verhoeven; Ingrid Bugánová; Sten Madsbad
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Diabetes care 2007;30(6):1608-10.
2007: Tina Vilsbøll; Filip K Knop
[Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus].
Ugeskrift for laeger 2007;169(22):2101-5.
2007: Filip K Knop; Tina Vilsbøll
[GLP-1-based treatment of type 2 diabetes mellitus].
Ugeskrift for laeger 2007;169(22):2095-9.
2007: Filip K Knop; Tina Vilsbøll; Sten Madsbad; Jens Juul Holst; Thure Krarup
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.
Diabetologia 2007;50(4):797-805.
2007: Tina Vilsbøll
Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.
Expert opinion on investigational drugs 2007;16(2):231-7.
2007: Katarzyna Cypryk; Tina Vilsbøll; Iwona Nadel; Joanna Smyczyńska; Jens Juul Holst; Andrzej Lewiński
Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2007;23(1):58-62.
2007: Filip K Knop; Tina Vilsbøll; Steen Larsen; Patricia V Højberg; Aage Voelund; Sten Madsbad; Jens J Holst; Thure Krarup
Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.
American journal of physiology. Endocrinology and metabolism 2007;292(1):E324-30.
2006: Tina Vilsbøll; Henrik Agersø; Torsten Lauritsen; Carolyn F Deacon; Kasper Aaboe; Sten Madsbad; Thure Krarup; Jens Juul Holst
The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.
Regulatory peptides 2006;137(3):168-72.
2006: Jakob Ryskjaer; Carolyn F Deacon; Richard D Carr; Thure Krarup; Sten Madsbad; Jens Holst; Tina Vilsbøll
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
European journal of endocrinology / European Federation of Endocrine Societies 2006;155(3):485-93.
2005: Jakob Hagen Schou; Kasper Pilgaard; Tina Vilsbøll; Christine B Jensen; Carolyn F Deacon; Jens Juul Holst; Aage Voelund; Sten Madsbad; Allan Vaag
Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
The Journal of clinical endocrinology and metabolism 2005;90(8):4912-9.
2004: Tina Vilsbøll
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Danish medical bulletin 2004;51(4):364-70.
2004: Cathrine Ørskov; Siv A Hjorth; Anne D Jensen; Tina Vilsbøll
Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes.
Regulatory peptides 2004;119(3):151-4.
2003: Dennis B Henriksen; Peter Alexandersen; Nina H Bjarnason; Tina Vilsbøll; Bolette Hartmann; Eva E G Henriksen; Inger Byrjalsen; Thure Krarup; Jens J Holst; Claus Christiansen
Role of gastrointestinal hormones in postprandial reduction of bone resorption.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(12):2180-9.
2003: Tina Vilsbøll; Filip K Knop; Thure Krarup; A Johansen; Sten Madsbad; Steen Larsen; T Hansen; O Pedersen; Jens Juul Holst
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
The Journal of clinical endocrinology and metabolism 2003;88(10):4897-903.
2003: Filip K Knop; Tina Vilsbøll; Steen Larsen; Sten Madsbad; Jens J Holst; Thure Krarup
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
Diabetes care 2003;26(9):2581-7.
2003: Tina Vilsbøll; Thure Krarup; Sten Madsbad; Jens J Holst
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Regulatory peptides 2003;114(2-3):115-21.
2003: Tina Vilsbøll; Thure Krarup; J Sonne; Sten Madsbad; Aage Voelund; A G Juul; Jens Juul Holst
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
The Journal of clinical endocrinology and metabolism 2003;88(6):2706-13.
2003: Tina Vilsbøll; Henrik Agersø; Thure Krarup; Jens Juul Holst
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
The Journal of clinical endocrinology and metabolism 2003;88(1):220-4.
2002: Tina Vilsbøll; Thure Krarup; Sten Madsbad; Jens Juul Holst
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Diabetologia 2002;45(8):1111-9.
2001: Tina Vilsbøll; Thure Krarup; Carolyn F Deacon; Sten Madsbad; Jens Juul Holst
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
Diabetes 2001;50(3):609-13.
2001: Tina Vilsbøll; Thure Krarup; Sten Madsbad; Jens Juul Holst
No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
Diabetic medicine : a journal of the British Diabetic Association 2001;18(2):144-9.
2000: Tina Vilsbøll; MB Toft-Nielsen; Thure Krarup; Sten Madsbad; B Dinesen; Jens Juul Holst
Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Diabetes care 2000;23(6):807-12.